Endothelium-derived hyperpolarizing factor mediates bradykinin-stimulated tissue plasminogen activator release in humans

Journal of Vascular Research

Volumn 51, Issue 3, 2014, Pages 200-208

  Rahman, Ayaz M ^a   Murrow, Jonathan R ^a   Ozkor, Muhiddin A ^a   Kavtaradze, Nino ^a   Lin, Ji ^b   De Staercke, Christine ^c   Hooper, W Craig ^c   Manatunga, Amita ^b   Hayek, Salim ^a   Quyyumi, Arshed A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Bradykinin; Endothelium; Endothelium derived hyperpolarizing factors; Fibrinolysis; Tissue plasminogen activator

Indexed keywords

BRADYKININ; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; FLUCONAZOLE; N(G) METHYLARGININE; NITROPRUSSIDE SODIUM; TETRYLAMMONIUM CHLORIDE; TISSUE PLASMINOGEN ACTIVATOR; NITRIC OXIDE; PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOREARM BLOOD FLOW; HUMAN; HUMAN EXPERIMENT; HYPERPOLARIZATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; VASCULAR ENDOTHELIUM; VASODILATATION; ENZYME ACTIVATION; ENZYME RELEASE; FIBRINOLYSIS; FOREARM; HUMAN TISSUE; MEASUREMENT; REST; VASCULARIZATION;

ADULT; BIOLOGICAL FACTORS; BRADYKININ; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; FLUCONAZOLE; FOREARM; HUMANS; MALE; MIDDLE AGED; NITROPRUSSIDE; OMEGA-N-METHYLARGININE; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; REGIONAL BLOOD FLOW; TETRAETHYLAMMONIUM; TISSUE PLASMINOGEN ACTIVATOR; VASODILATION;

EID: 84902032222     PISSN: 10181172     EISSN: 14230135     Source Type: Journal    
DOI: 10.1159/000362666     Document Type: Article

References (58)

1. Newby DE, Wright RA, Labinjoh C, LudlamCA, Fox KA, Boon NA, Webb DJ: Endothelialdysfunction, impaired endogenousfibrinolysis, and cigarette smoking: amechanism for arterial thrombosis andmyocardial infarction. Circulation 1999; 99:1411-1415.
2. Newby DE, McLeod AL, Uren NG, Flint L,Ludlam CA, Webb DJ, Fox KA, Boon NA:Impaired coronary tissue plasminogen activatorrelease is associated with coronary atherosclerosisand cigarette smoking: directlink between endothelial dysfunction andatherothrombosis. Circulation 2001; 103:1936-1941.
3. Feletou M, Vanhoutte PM: Endothelium-dependenthyperpolarizations: past beliefs andpresent facts. Ann Med 2007; 39: 495-516.
4. Ozkor MA, Murrow JR, Rahman AM, KavtaradzeN, Lin J, Manatunga A, Quyyumi AA:Endothelium-derived hyperpolarizing factordetermines resting and stimulated forearmvasodilator tone in health and in disease. Circulation2011; 123: 2244-2253.
5. Vanhoutte PM: Endothelium and control ofvascular function. State of the art lecture. Hypertension1989; 13: 658-667.
6. Brown NJ, Gainer JV, Stein CM, VaughanDE: Bradykinin stimulates tissue plasminogenactivator release in human vasculature. Hypertension 1999; 33: 1431-1435.
7. Linz W, Wiemer G, Scholkens BA: Beneficialeffects of bradykinin on myocardial energymetabolism and infarct size. Am J Cardiol1997; 80: 118A-123A.
8. Emeis JJ, van den Eijnden-Schrauwen Y, vanden Hoogen CM, de Priester W, WestmuckettA, Lupu F: An endothelial storage granulefor tissue-type plasminogen activator. J CellBiol 1997; 139: 245-256.
9. Fox KA, Robison AK, Knabb RM, RosamondTL, Sobel BE, Bergmann SR: Prevention ofcoronary thrombosis with subthrombolyticdoses of tissue-type plasminogen activator. Circulation 1985; 72: 1346-1354.
10. Schmaier AH: The plasma kallikrein-kininsystem counterbalances the renin-Angiotensinsystem. J Clin Invest 2002; 109: 1007-1009.
11. Brown NJ, Gainer JV, Murphey LJ, VaughanDE: Bradykinin stimulates tissue plasminogenactivator release from human forearmvasculature through B 2 receptor-dependent,NO synthase-independent, and cyclooxygenase-independent pathway. Circulation 2000;102: 2190-2196.
12. Node K, Ruan XL, Dai J, Yang SX, Graham L,Zeldin DC, Liao JK: Activation of Galpha smediates induction of tissue-type plasminogenactivator gene transcription by epoxyeicosatrienoicacids. J Biol Chem 2001; 276:15983-15989.
13. Muldowney JA 3rd, Painter CA, Sanders-Bush E, Brown NJ, Vaughan DE: Acute tissuetypeplasminogen activator release in humanmicrovascular endothelial cells: the roles ofGalphaq, PLC-beta, ip3 and 5,6-epoxyeicosatrienoicacid. Thromb Haemost 2007; 97: 263-271.
14. Halcox JP, Narayanan S, Cramer-Joyce L,Mincemoyer R, Quyyumi AA: Characterizationof endothelium-derived hyperpolarizingfactor in the human forearm microcirculation. Am J Physiol Heart Circ Physiol 2001;280:H2470-H2477.
15. Scotland RS, Madhani M, Chauhan S, MoncadaS, Andresen J, Nilsson H, Hobbs AJ, AhluwaliaA: Investigation of vascular responses inendothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: key role forendothelium-derived hyperpolarizing factorin the regulation of blood pressure in vivo. Circulation 2005; 111: 796-803.
16. Inokuchi K, Hirooka Y, Shimokawa H, SakaiK, Kishi T, Ito K, Kimura Y, Takeshita A: Roleof endothelium-derived hyperpolarizing factorin human forearm circulation. Hypertension2003; 42: 919-924.
17. Bellien J, Iacob M, Gutierrez L, Isabelle M, LaharyA, Thuillez C, Joannides R: Crucial roleof NO and endothelium-derived hyperpolarizingfactor in human sustained conduit arteryflow-mediated dilatation. Hypertension2006; 48: 1088-1094.
18. Miura H, Wachtel RE, Liu Y, Loberiza FR Jr,Saito T, Miura M, Gutterman DD: Flow-induceddilation of human coronary arterioles:important role of Ca(2+)-Activated K(+)channels. Circulation 2001; 103: 1992-1998.
19. Bellien J, Joannides R, Iacob M, Arnaud P,Thuillez C: Evidence for a basal release of acytochrome-related endothelium-derived hyperpolarizingfactor in the radial artery in humans. Am J Physiol Heart Circ Physiol 2006;290:H1347-H1352.
20. Hong SL: Effect of bradykinin and thrombinon prostacyclin synthesis in endothelial cellsfrom calf and pig aorta and human umbilicalcord vein. Thromb Res 1980; 18: 787-795.
21. Duffy SJ, Tran BT, New G, Tudball RN, EslerMD, Harper RW, Meredith IT: Continuous releaseof vasodilator prostanoids contributes toregulation of resting forearm blood flow in humans. Am J Physiol 1998; 274:H1174-H1183.
22. Honing ML, Smits P, Morrison PJ, RabelinkTJ: Bradykinin-induced vasodilation of humanforearm resistance vessels is primarilymediated by endothelium-dependent hyperpolarization. Hypertension 2000; 35: 1314-1318.
23. Stanfield PR: Tetraethylammonium ions andthe potassium permeability of excitable cells. Rev Physiol Biochem Pharmacol 1983; 97: 1-67.
24. Langton PD, Nelson MT, Huang Y, StandenNB: Block of calcium-Activated potassiumchannels in mammalian arterial myocytes bytetraethylammonium ions. Am J Physiol1991; 260:H927-H934.
25. Gilligan DM, Guetta V, Panza JA, Garcia CE,Quyyumi AA, Cannon RO 3rd: Selective lossof microvascular endothelial function in humanhypercholesterolemia. Circulation 1994;90: 35-41.
26. Ridker PM, Vaughan DE, Stampfer MJ, MansonJE, Shen C, Newcomer LM, GoldhaberSZ, Hennekens CH: Baseline fibrinolytic stateand the risk of future venous thrombosis. Aprospective study of endogenous tissue-typeplasminogen activator and plasminogen activatorinhibitor. Circulation 1992; 85: 1822-1827.
27. Giannarelli C, Virdis A, De Negri F, MagagnaA, Duranti E, Salvetti A, Taddei S: Effect ofsulfaphenazole on tissue plasminogen activatorrelease in normotensive subjects and hypertensivepatients. Circulation 2009; 119:1625-1633.
28. Gorog DA: Prognostic value of plasma fibrinolysisactivation markers in cardiovasculardisease. J Am Coll Cardiol 2010; 55: 2701-2709.
29. Rijken DC, Lijnen HR: New insights into themolecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009; 7: 4-13.
30. Stein CM, Brown N, Vaughan DE, Lang CC,Wood AJ: Regulation of local tissue-type plasminogenactivator release by endotheliumdependentand endothelium-independentagonists in human vasculature. J Am CollCardiol 1998; 32: 117-122.
31. van den Eijnden-Schrauwen Y, Atsma DE,Lupu F, de Vries RE, Kooistra T, Emeis JJ: Involvementof calcium and G proteins in theacute release of tissue-type plasminogen activatorand von Willebrand factor from culturedhuman endothelial cells. ArteriosclerThromb Vasc Biol 1997; 17: 2177-2187.
32. Fleming I, Michaelis UR, Bredenkotter D,Fisslthaler B, Dehghani F, Brandes RP, BusseR: Endothelium-derived hyperpolarizing factorsynthase (cytochrome P450 2C9) is a functionallysignificant source of reactive oxygenspecies in coronary arteries. Circ Res 2001; 88:44-51.
33. Lambeth JD: Nox enzymes, ROS, and chronicdisease: an example of antagonistic pleiotropy. Free Radic Biol Med 2007; 43: 332-347.
34. Witherow FN, Dawson P, Ludlam CA, WebbDJ, Fox KA, Newby DE: Bradykinin receptorantagonism and endothelial tissue plasminogenactivator release in humans. ArteriosclerThromb Vasc Biol 2003; 23: 1667-1670.
35. Fisslthaler B, Popp R, Kiss L, Potente M,Harder DR, Fleming I, Busse R: CytochromeP450 2C is an EDHF synthase in coronary arteries. Nature 1999; 401: 493-497.
36. Campbell WB, Gebremedhin D, Pratt PF,Harder DR: Identification of epoxyeicosatrienoicacids as endothelium-derived hyperpolarizingfactors. Circ Res 1996; 78: 415-423.
37. Weston AH, Feletou M, Vanhoutte PM, FalckJR, Campbell WB, Edwards G: Bradykinininduced,endothelium-dependent responsesin porcine coronary arteries: involvement ofpotassium channel activation and epoxyeicosatrienoicacids. Br J Pharmacol 2005; 145:775-784.
38. Gauthier KM, Edwards EM, Falck JR, ReddyDS, Campbell WB: 14,15-Epoxyeicosatrienoicacid represents a transferable endotheliumdependentrelaxing factor in bovine coronaryarteries. Hypertension 2005; 45: 666-671.
39. Fleming I: Cytochrome P450 and vascular homeostasis. Circ Res 2001; 89: 753-762.
40. Fleming I, Busse R: Endothelium-derived epoxyeicosatrienoicacids and vascular function. Hypertension 2006; 47: 629-633.
41. Feletou M, Vanhoutte PM: Endothelium-derivedhyperpolarizing factor: where are wenow? Arterioscler Thromb Vasc Biol 2006; 26:1215-1225.
42. Larsen BT, Gutterman DD, Sato A, Toyama K,Campbell WB, Zeldin DC, Manthati VL, FalckJR, Miura H: Hydrogen peroxide inhibits cytochromeP450 epoxygenases: interaction betweentwo endothelium-derived hyperpolarizingfactors. Circ Res 2008; 102: 59-67.
43. Winnerkvist A, Wiman B, Valen G, Vaage J:Oxidative stress and release of tissue plasminogenactivator in isolated rat hearts. ThrombRes 1997; 85: 245-257.
44. Matoba T, Shimokawa H, Kubota H, MorikawaK, Fujiki T, Kunihiro I, Mukai Y, HirakawaY, Takeshita A: Hydrogen peroxide isan endothelium-derived hyperpolarizing factorin human mesenteric arteries. BiochemBiophys Res Commun 2002; 290: 909-913.
45. Newby DE, Wright RA, Ludlam CA, FoxKAA, Boon NA, Webb DJ: An in vivo modelfor the assessment of acute fibrinolytic capacityof the endothelium. Thromb Haemost1997; 78: 1242-1248.
46. Pretorius M, Brown NJ: Endogenous nitricoxide contributes to bradykinin-stimulatedglucose uptake but attenuates vascular tissuetypeplasminogen activator release. J PharmacolExp Ther 2010; 332: 291-297.
47. Rees DD, Palmer RM, Hodson HF, MoncadaS: A specific inhibitor of nitric oxide formationfrom L-Arginine attenuates endotheliumdependentrelaxation. Br J Pharmacol 1989;96: 418-424.
48. Coleman HA, Tare M, Parkington HC: Endothelialpotassium channels, endothelium-dependenthyperpolarization and the regulationof vascular tone in health and disease. ClinExp Pharmacol Physiol 2004; 31: 641-649.
49. Akk G, Steinbach JH: Activation and block ofmouse muscle-type nicotinic receptors by tetraethylammonium. J Physiol 2003; 551: 155-168.
50. Brooks HL, Regan JW, Yool AJ: Inhibition ofaquaporin-1 water permeability by tetraethylammonium:involvement of the loop E poreregion. Mol Pharmacol 2000; 57: 1021-1026.
51. Halcox JPJ, Narayanan S, Cramer-Joyce L,Mincemoyer R, Quyyumi AA: Characterizationof endothelium-derived hyperpolarizingfactor in the human forearm microcirculation. Am J Physiol Heart Circ Physiol 2001;280:H2470-H2477.
52. Fichtlscherer S, Dimmeler S, Breuer S, BusseR, Zeiher AM, Fleming I: Inhibition of cytochromeP450 2C9 improves endothelium-dependent,nitric oxide-mediated vasodilatationin patients with coronary artery disease. Circulation 2004; 109: 178-183.
53. Passauer J, Bussemaker E, Lassig G, PistroschF, Fauler J, Gross P, Fleming I: Baseline bloodflow and bradykinin-induced vasodilator responsesin the human forearm are insensitiveto the cytochrome P450 2C9 (CYP2C9) inhibitorsulphaphenazole. Clin Sci (Lond)2003; 105: 513-518.
54. Rosenbaum DA, Pretorius M, Gainer JV, ByrneD, Murphey LJ, Painter CA, Vaughan DE,Brown NJ: Ethnicity affects vasodilation, butnot endothelial tissue plasminogen activatorrelease, in response to bradykinin. ArteriosclerThromb Vasc Biol 2002; 22: 1023-1028.
55. Ohlmann P, Martinez MC, Schneider F, StocletJC, Andriantsitohaina R: Characterizationof endothelium-derived relaxing factorsreleased by bradykinin in human resistancearteries. Br J Pharmacol 1997; 121: 657-664.
56. Nakashima M, Mombouli JV, Taylor AA,Vanhoutte PM: Endothelium-dependent hyperpolarizationcaused by bradykinin in humancoronary arteries. J Clin Invest 1993; 92:2867-2871.
57. Halcox JP, Schenke WH, Zalos G, MincemoyerR, Prasad A, Waclawiw MA, Nour KR,Quyyumi AA: Prognostic value of coronaryvascular endothelial dysfunction. Circulation2002; 106: 653-658.
58. Ridker PM, Vaughan DE, Stampfer MJ, MansonJE, Hennekens CH: Endogenous tissuetypeplasminogen activator and risk of myocardialinfarction. Lancet 1993; 341: 1165-1168.